Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

GLP-1 Receptor Agonists: What Are the Side Effects?

Medically reviewed by 
GLP-1 Receptor Agonists: What Are the Side Effects?

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of metabolic medications for the treatment of type 2 diabetes mellitus and obesity. While they are notably efficacious for many patients, they come with several potential adverse effects

Patient awareness for informed decision-making is important when formulating a treatment plan that includes  GLP-1 receptor agonists. By discussing the possible side effects associated with GLP-1 receptor agonists, this article aims to provide an understanding of treatment-related complications to improve patient safety and desired positive outcomes.


What Are GLP-1 Receptor Agonists?

Glucagon-like peptide-1 (GLP-1) is a neurohormone released in the intestines in response to food intake. It serves to increase glucose uptake into tissues to balance blood sugar. It also reduces glucose release from the liver and other tissues, delays gastric emptying promotes fullness, and thus reduces appetite. GLP-1 receptor agonists bind to GLP-1 receptors, thereby augmenting the activity of GLP-1. Indirectly, the effects of GLP-1 receptor agonists improve insulin sensitivity and help control blood glucose. 

Beyond glycemic control, GLP-1 receptor agonists are advantageous in weight management. By increasing satiety, slowing gastric emptying, and reducing appetite, they help reduce caloric intake and increase weight loss. The delayed gastric emptying helps sustain fullness over time, increasing the time between meals. The ability of GLP-1 agonists to increase weight loss further increases their ability to control blood glucose, increasing their therapeutic utility.

Side Effects of GLP-1 Receptor Agonists

GLP-1 receptor agonists are known to cause several potential adverse effects

  • Gastrointestinal problems occur most frequently. Nausea, vomiting, diarrhea, and constipation are common among patients taking GLP-1 receptor agonists. These adverse effects may be severe enough to discontinue treatment. 
  • Injection site reactions also occur with GLP-1 receptor agonists in injectable forms. Redness, swelling, and pain at the injection site may occur, but it usually resolves within a few days.
  • A decrease in appetite is a significant, but expected, side effect of GLP-1 receptor agonists, and it often leads to reduced calorie intake, supporting the overall goals of glycemic control and weight management. 
  • GLP-1 receptor agonists are known to increase the risk of pancreatitis, albeit rare. It is important to monitor for symptoms of pancreatitis, including severe midline abdominal pain radiating to the back, with nausea and vomiting. Pancreatitis can be severe and lead to serious complications if not treated.
  • Hypoglycemia is also a potential risk, especially when GLP-1 receptor agonists are used in combination with other diabetes medications that reduce blood sugar, like insulin or sulfonylureas. Shakiness, fatigue, and reduced mental clarity are commonly seen in hypoglycemic episodes. Prompt correction is necessary to reduce the risk of serious complications.
  • Because of the risk of thyroid cancer, GLP-1 receptor agonists should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Managing and Minimizing Side Effects

Effectively managing the side effects of GLP-1 receptor agonists side effects requires a team approach. 

  • Gastrointestinal side effects can be minimized by initiating treatment at a low dose and titrating up slowly.
  • For oral formulations, taking the medication with food can help reduce side effect severity. Dietary modifications, including smaller, more frequent, high-fiber meals can also help.
  • Injection site reactions are less common if patients rotate injection sites and use proper injection techniques. Cold compresses can help reduce pain.
  • Regular monitoring of symptoms and following the prescribed regimen is vital to reduce side effects and improve tolerance. Routine follow-up appointments are necessary to monitor weight and other vital signs, as well as laboratory testing, and closely monitoring for adverse effects. 

Educating patients to recognize side effects, plus encouraging open communication between healthcare providers and patients, increases treatment adherence and encourages better outcomes. 

Considerations Before Starting GLP-1 Receptor Agonists

Before starting treatment with a GLP-1 receptor agonist, consider the following:

Comprehensive Medical Evaluation

A comprehensive medical evaluation is necessary to weigh the risks and benefits of treatment, focusing on factors such as gastrointestinal health, thyroid function, risk factors for cardiovascular disease, and weight. Shared decision-making between the healthcare professional and the patient must include a discussion of potential side effects and risks associated with GLP-1 receptor agonists to enable informed decision-making.

Personalized Treatment Plans

Personalized treatment plans, tailored to individual goals and health factors, like comorbid conditions, current medications, diet history, and patient preferences are necessary to determine the appropriateness of treatment GLP-1 receptor agonists. Understand that GLP-1 receptor agonists are not in place of lifestyle modifications, but instead are a complementary treatment modality.


Key Takeaways

Glucagon-like peptide-1 (GLP-1) receptor agonists are notably efficacious for many patients. However, they come with several potential adverse effects, the most common of which are gastrointestinal side effects, which may be mitigated with certain strategies. However, other side effects may be severe, so it is vital to make an informed decision considering the risks and benefits of GLP-1 receptor agonist therapy.

The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No items found.

Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther. 2021;38(6):2821–2839.

Chis BA, Fodor D. Acute pancreatitis during GLP-1 receptor agonist treatment. A case report. Clujul Med. 2018;91(1):117–119.

Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022;12(1):145.

Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2014;11(3-4):202–230.

Hearn EB, Sherman JJ. Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide. Diabetes Spectr. 2021;34(1):73–75.

Lee, S. (2024, February 29). GLP-1 Drugs and Exercise: The Magic Combo for Weight Management? Rupa Health.

Lee, S. (2024, February 9). What Are GLP-1 Drugs, and Why Are They Becoming Popular? Rupa Health.

Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130.

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.

Rodbard HW. The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. Diabetes Technol Ther. 2018;20(S2):S233–S241.

Silverii GA, Monami M, Gallo M, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(3):891–900.

Yoshimura, H. (2023, July 17.) Using Functional Medicine as Personalized Medicine. Rupa Health.

Zhao X, Wang M, Wen Z, et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021;12:721135.

Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.